Anand Seshadri

Senior Director

Alvarez & Marsal

Office Phone:

(973) 871-2040


  Pro - Try 1 Week Free
 

    and access,

  •     81K PE/M&A Contacts
  •     +
  •     4.6K PE Firms
  •     3.6K M&A Advisors
  •     202K Transactions
  •     205K Companies

  •     Market Services
  •     Build Lists
  •     Research Sectors
  •     Uncover Opportunities

Bio

Anand Seshadri is a Senior Director with Alvarez & Marsal’s Corporate Transactions Group in Morristown. He specializes in advising corporate clients through complex transactional and transformational initiatives, including M&A strategy, integrations, carve-outs and divestitures, and performance improvement. With more than 15 years of experience spanning industry and advisory roles, Mr. Seshadri brings deep expertise across complex M&A areas, including commercial and operational diligence, cross-border integration/separation planning and execution, operating model design and performance improvement strategies. He leverages his engineering background, analytics capabilities and business acumen to deliver tailored, data-driven and holistic insights to clients across strategic, operational and financial matters from transactional to transformational initiatives. Prior to joining A&M, Mr. Seshadri spent nine years with KPMG’s Deal Advisory & Strategy practice, advising global clients across healthcare and life sciences, financial services, and aerospace and defense sectors on due diligence, post-merger integrations and carve-outs. Notably, Mr. Seshadri advised on the global post-merger integration for a large, multinational life sciences company in support of a $63 billion acquisition; led the post-merger integration for an EU-based life sciences company in support of an $800 million U.S. biotech acquisition; oversaw a $1 billion divestment for the generics subsidiary of a large multinational pharmaceutical company; and performed operational due diligence for an industrials company looking to acquire a market competitor. Mr. Seshadri earned a bachelor’s degree in computer engineering from Tufts University and an MBA from Georgetown University’s McDonough School of Business. Additionally, he holds a certificate from the Artificial Intelligence in Pharma and Biotech program at MIT’s Sloan School of Management.

Education